1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Myovant Ready To File Relugolix For Prostate Cancer

 
• By Joseph Haas

Secondary endpoint assessing cardiovascular risk may offer important differentiation from AbbVie’s Lupron. Myovant accelerated the prostate cancer filing soon after slowing the planned relugolix submission for uterine fibroids.

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours
Myovant now is on pace for two FDA filings of relugolix in 2020

Myovant Sciences Ltd. said it has met the regulatory standards it will need to file its daily, oral GnRH receptor antagonist relugolix for approval in advanced prostate cancer both within and outside the US, so the Swiss firm now has US Food and Drug Administration filings for both prostate cancer and uterine fibroids on tap in 2020.

CEO Lynn Seely told an investor call on 19 November that, in the second quarter, Myovant will file a new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Alnylam Pairs Zilebesiran With Diuretics After Phase II Endpoint Miss In Hypertension

 
• By Manas Mishra

Alnylam and Roche refine zilebesiran’s Phase III trial design after a Phase II miss, focusing on patients on diuretics.

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 
• By Andrew McConaghie

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 
• By Alaric DeArment

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

J&J Keeps Faith In Nipocalimab’s $5bn Sales Target Despite RA Trial Setback

 
• By Manas Mishra

Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.

More from R&D

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

Lilly’s Verzenio Scores First OS Improvement In Key Breast Cancer Setting In Decades

 
• By Alaric DeArment

The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.

Psychedelic Drug Development Shows Promise, But Market Path Remains Steep

 
• By Sushmita Panda

With late-stage trials advancing and regulatory guidance in place, psychedelic medicines are nearing a pivotal moment in their path to market. Success will hinge on overcoming clinical, logistical and commercial challenges.